BlackRock
PYXS icon

BlackRock’s Pyxis Oncology PYXS Stock Holding History

BlackRock’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Buy
788,839
+4,762
+0.6% +$7.18K ﹤0.01% 4291
2025
Q4 		$902K Buy
784,077
+100,375
+15% +$354K ﹤0.01% 4332
2025
Q3 		$1.52M Sell
683,702
-243,103
-26% -$350K ﹤0.01% 4179
2025
Q2 		$1.02M Sell
926,805
-2,345,169
-72% -$2.64M ﹤0.01% 4246
2025
Q1 		$3.21M Sell
3,271,974
-72,167
-2% -$96.3K ﹤0.01% 3820
2024
Q4 		$5.22M Buy
3,344,141
+379,981
+13% +$1.1M ﹤0.01% 3709
2024
Q3 		$10.9M Buy
2,964,160
+178,265
+6% +$624K ﹤0.01% 3358
2024
Q2 		$9.22M Buy
2,785,895
+2,464,230
+766% +$10.4M ﹤0.01% 3428
2024
Q1 		$1.37M Buy
321,665
+11,067
+4% +$46.5K ﹤0.01% 4113
2023
Q4 		$559K Buy
310,598
+9,084
+3% +$15.6K ﹤0.01% 4397
2023
Q3 		$600K Buy
301,514
+33,077
+12% +$76.6K ﹤0.01% 4374
2023
Q2 		$687K Buy
268,437
+56,149
+26% +$178K ﹤0.01% 4395
2023
Q1 		$851K Buy
212,288
+956
+0.5% +$1.91K ﹤0.01% 4379
2022
Q4 		$283K Buy
211,332
+4,778
+2% +$7.17K ﹤0.01% 4754
2022
Q3 		$406K Buy
206,554
+1,250
+0.6% +$3.27K ﹤0.01% 4788
2022
Q2 		$489K Sell
205,304
-315,597
-61% -$840K ﹤0.01% 4778
2022
Q1 		$2.1M Buy
520,901
+7,053
+1% +$51.6K ﹤0.01% 4367
2021
Q4 		$5.64M Buy
+513,848
New +$5.88M ﹤0.01% 3944

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

BlackRock's PYXS Position: Q1 2026 in Review

BlackRock increased its Pyxis Oncology (PYXS) stake by 0.61% in Q1 2026, buying an estimated $7.18K and bringing the position to 788,839 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #4291.

BlackRock first reported a position in PYXS in Q4 2021 and has held it in 18 quarters since. The position peaked at $10.9M in Q3 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • BlackRock held 788,839 shares of Pyxis Oncology worth $1.15M as of Q1 2026.
  • BlackRock bought 4,762 Pyxis Oncology shares in Q1 2026, an estimated $7.18K.
  • Pyxis Oncology made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4291 holding.
  • BlackRock first reported a position in Pyxis Oncology in Q4 2021 and has held it in 18 quarters since.
  • BlackRock's Pyxis Oncology position peaked at $10.9M in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.